Cargando…

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance

Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwak, Yee Gyung, Song, Je Eun, Kang, Jieun, Kang, Jiyeon, Kang, Hyung Koo, Koo, Hyeon-Kyoung, Park, Hye Kyeong, Choi, Sang Bong, Lee, Hyuk Pyo, Lee, Myung Jin, Kim, Baek-Nam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840967/ https://www.ncbi.nlm.nih.gov/pubmed/36226346 http://dx.doi.org/10.3947/ic.2022.0103

Ejemplares similares

Impact of prior vaccination on clinical outcomes of patients with COVID-19
por: Seo, Woo Jung, et al.
Publicado: (2022)

Prediction models for respiratory outcomes in patients with COVID-19: integration of quantitative computed tomography parameters, demographics, and laboratory features
por: Kang, Jieun, et al.
Publicado: (2023)

Quantitative Computed Tomography Parameters in Coronavirus Disease 2019 Patients and Prediction of Respiratory Outcomes Using a Decision Tree
por: Kang, Jieun, et al.
Publicado: (2022)

Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

Unilateral diffuse alveolar haemorrhage with microscopic polyangiitis: A case report
por: Kim, Tae Gyoung, et al.
Publicado: (2023)

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

Association of rheumatoid arthritis with bronchial asthma and asthma-related comorbidities: A population-based national surveillance study
por: Kim, Jung Gon, et al.
Publicado: (2023)

Clinical phenotypes of chronic cough categorised by cluster analysis
por: Kang, Jiyeon, et al.
Publicado: (2023)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Systemic White Blood Cell Count as a Biomarker Associated with Severity of Chronic Obstructive Lung Disease
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2017)

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
por: Kim, Haein, et al.
Publicado: (2023)

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

Hand grip strength in patients with chronic obstructive pulmonary disease
por: Jeong, Moa, et al.
Publicado: (2017)

A case of bacterial keratitis caused by multi-drug-resistant Shewanella algae without marine exposure
por: Song, Je Eun, et al.
Publicado: (2021)

The Use of Lung Ultrasound in a Surgical Intensive Care Unit
por: Kang, Hyung Koo, et al.
Publicado: (2017)

How to deal with the Delta variant this fall
por: Lee, Jong-Koo
Publicado: (2021)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
por: McSweeney, Morgan D., et al.
Publicado: (2022)

The Use of Inappropriate Antibiotics in Patients Admitted to Intensive Care Units with Nursing Home–Acquired Pneumonia at a Korean Teaching Hospital
por: Kim, Deok Hee, et al.
Publicado: (2020)

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells
por: Park, Hyun Jin, et al.
Publicado: (2019)

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
por: Lee, Shinwon, et al.
Publicado: (2022)

Cough Characteristics and Their Association Patterns According to Cough Etiology: A Network Analysis
por: Kang, Jieun, et al.
Publicado: (2023)

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database
por: Seo, Woo Jung, et al.
Publicado: (2023)

Survey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea
por: Song, Je Eun, et al.
Publicado: (2021)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
por: Lee, Ji Yeon, et al.
Publicado: (2023)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
por: Chae, Ganghee, et al.
Publicado: (2022)

Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Publicado: (2023)

Comparison of the Seroprevalence of Measles Antibodies among Healthcare Workers in Two Korean Hospitals in 2019
por: Kwak, Yee Gyung, et al.
Publicado: (2020)

Rapid and simultaneous purification of aflatoxin B1, zearalenone and deoxynivalenol using their monoclonal antibodies and magnetic nanoparticles
por: Lee, Hyuk-Mi, et al.
Publicado: (2021)

Consistency of models with CP violation predominantly in the DELTA.S=1 Hamiltonian
por: Hagelin, John S
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_pqstfqsjuoo6419fdco916fkle